Trump Plans Tax Cuts, Deregulation After Meeting with Pharma Lobbyists

Source: Reuters

Jan 31, 2017

After a meeting with pharmaceutical industry lobbyists today Trump has stated plans to lower taxes and to loosen regulations. Executives from J&J, Eli Lilly, Merck, Amgen Inc, Novartis and more attended as well.

Trump called on the pharma industry to manufacture more drugs in the United States and to cut prices. In a statement, Trump promised to "streamline the FDA." He admonished the pharma industry over "astronomical" medicine prices in its health programs for older, disabled and poor people and stated he would appoint a new U.S. Food and Drug Administration leader shortly.

"We’re going to streamline the FDA," Trump said in a statement, referring to the regulatory agency responsible for vetting that new drugs are safe and effective.

According to a Reuters report, Celgene, Lilly, Merck and Amgen were encouraged by Trump's focus on innovation, tax reform and the need for a more value-driven health care system.

Read the Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments